tradingkey.logo
tradingkey.logo
Search

Aprea Therapeutics Inc

APRE
Add to Watchlist
0.632USD
+0.004+0.70%
Close 07-24 16:00ETQuotes delayed by 15 min
7.57MMarket Cap
LossP/E TTM

Earnings Forecast

Currency: USD Updated: 2026-07-24
Previous score
9.00
Change
0
The current earnings forecast score of Aprea Therapeutics Inc is 9.00, ranking 16 out of 386 in the Biotechnology & Medical Research industry. The average price target is 10.50, with a high of 11.00 and a low of 10.00.

Analyst Rating

Based on 4 analysts
Strong Buy
Current Rating
4.300
Target Price
+581.46%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell

Peer Comparison

496
Total
6
Median
7
Average
Company name
Ratings
Analysts
Aprea Therapeutics Inc
APRE
4
Beigene Ltd
ONC
28
Ionis Pharmaceuticals Inc
IONS
27
argenx SE
ARGX
26
IQVIA Holdings Inc
IQV
26
Insmed Inc
INSM
23
1
2
3
...
99

Support & Resistance

Relevant data have not been disclosed by the company yet.

Financial Forecasting

EPS
Revenue
Net Profit
EBIT
Forecast
Actual

FAQs

What is Aprea Therapeutics Inc's expected revenue for the next quarter?

Aprea Therapeutics Inc's expected revenue is 168.67K.

What is Aprea Therapeutics Inc's price target?

Analysts forecast that Aprea Therapeutics Inc's price target is USD 10.50, with the highest forecast at USD 11.00 and the lowest forecast at USD 10.00.

How have Aprea Therapeutics IncAPRE's recent earnings per share performed?

The market expectation was USD -0.22, while Aprea Therapeutics IncAPRE's earnings per share (EPS) for the previous quarter was USD -0.32. EPS for the next quarter is expected at USD -0.23.

What is the analyst rating for Aprea Therapeutics Inc?

Based on the ratings of Aprea Therapeutics Inc's stock from 4 analysts, most analysts support a STRONG BUY trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as STRONG BUY. Please note that this is not trading advice. You still need to conduct your own analysis.
tradingkey.logo
Risk Warning: Our Website and Mobile App provides only general information on certain investment products. Finsights does not provide, and the provision of such information must not be construed as Finsights providing, financial advice or recommendation for any investment product.
Investment products are subject to significant investment risks, including the possible loss of the principal amount invested and may not be suitable for everyone. Past performance of investment products is not indicative of their future performance.
Finsights may allow third party advertisers or affiliates to place or deliver advertisements on our Website or Mobile App or any part thereof and may be compensated by them based on your interaction with the advertisements.
© Copyright: FINSIGHTS MEDIA PTE. LTD. All Rights Reserved.